Drugs / BMS 777607
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01721148 | Oct 2012 → Dec 2016 | cancer | ASLAN Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00605618 | Mar 2008 → Mar 2009 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS 777607 | “A Phase I Multiple Ascending Dose Study of ASLAN002 (BMS 777607) in Subjects With Advanced or Metastatic Solid Tumours” NCT01721148 ↗ |
| Known as | ASLAN-002 | “ASLAN-002 is a potent inhibitor of MET as well as related kinases.” PMID 29766337 ↗ May 2018 |
| Action | Inhibit | “ASLAN-002 is a potent inhibitor of MET as well as related kinases.” PMID 29766337 ↗ May 2018 |
| Modality | Small molecule | — CHEMBL460702 ↗ |
| Route | Oral | “were administered ASLAN-002 orally.” PMID 29766337 ↗ May 2018 |
| Target | MET | “ASLAN-002 is a potent inhibitor of MET as well as related kinases.” PMID 29766337 ↗ May 2018 |